| Cornea And Contact Lens Institute Of Minnesota | |
|
5137 Gus Young Ln, Edina, MN 55436-1530 | |
| (952) 641-6226 | |
| Not Available |
| Full Name | Cornea And Contact Lens Institute Of Minnesota |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 5137 Gus Young Ln, Edina, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265733471 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | LD2631 (* (Not Available)) | Primary |
| 207W00000X | Ophthalmology | 44481 (Minnesota) | Secondary |
| Provider Name | Brooke Messer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1114239282 PECOS PAC ID: 8527256692 Enrollment ID: I20111031000770 |
News Archive
Rettsyndrome.org is pleased to share that Neuren Pharmaceuticals, today, after meeting with the FDA, will conduct a Phase 3 clinical trial for trofinetide, a compound that shows great promise in the treatment of Rett syndrome, in children and adults.
Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of its developmental retinitis pigmentosa (RP) treatment, jCell.
At the 64th ASMS Conference, Bruker introducesrapifleX™, the highest performance MALDI-TOF/TOF mass spectrometer, which had been shown as work-in-progress to early adopters at HUPO 2015.
People living with a child who attends school in-person have an increased risk of reporting evidence of COVID-19, but teacher masking, symptom screening, and other mitigation measures in schools may be able to minimize that excess risk, suggests a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Telephone-based counseling, when combined with physician advice, can help breast cancer survivors become more physically active, which can improve quality of life and lessen the side effects of cancer treatment, according to new research from The Miriam Hospital.
› Verified 2 days ago
| Provider Name | Zachary Holland |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1396125837 PECOS PAC ID: 6608158746 Enrollment ID: I20170124003122 |
News Archive
Rettsyndrome.org is pleased to share that Neuren Pharmaceuticals, today, after meeting with the FDA, will conduct a Phase 3 clinical trial for trofinetide, a compound that shows great promise in the treatment of Rett syndrome, in children and adults.
Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of its developmental retinitis pigmentosa (RP) treatment, jCell.
At the 64th ASMS Conference, Bruker introducesrapifleX™, the highest performance MALDI-TOF/TOF mass spectrometer, which had been shown as work-in-progress to early adopters at HUPO 2015.
People living with a child who attends school in-person have an increased risk of reporting evidence of COVID-19, but teacher masking, symptom screening, and other mitigation measures in schools may be able to minimize that excess risk, suggests a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Telephone-based counseling, when combined with physician advice, can help breast cancer survivors become more physically active, which can improve quality of life and lessen the side effects of cancer treatment, according to new research from The Miriam Hospital.
› Verified 2 days ago
| Provider Name | Katelyn L Schneider |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1689233447 PECOS PAC ID: 1951638501 Enrollment ID: I20190806001194 |
News Archive
Rettsyndrome.org is pleased to share that Neuren Pharmaceuticals, today, after meeting with the FDA, will conduct a Phase 3 clinical trial for trofinetide, a compound that shows great promise in the treatment of Rett syndrome, in children and adults.
Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of its developmental retinitis pigmentosa (RP) treatment, jCell.
At the 64th ASMS Conference, Bruker introducesrapifleX™, the highest performance MALDI-TOF/TOF mass spectrometer, which had been shown as work-in-progress to early adopters at HUPO 2015.
People living with a child who attends school in-person have an increased risk of reporting evidence of COVID-19, but teacher masking, symptom screening, and other mitigation measures in schools may be able to minimize that excess risk, suggests a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Telephone-based counseling, when combined with physician advice, can help breast cancer survivors become more physically active, which can improve quality of life and lessen the side effects of cancer treatment, according to new research from The Miriam Hospital.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cornea And Contact Lens Institute Of Minnesota Po Box 1170, Maple Grove, MN 55311-6170 Ph: (763) 746-2094 | Cornea And Contact Lens Institute Of Minnesota 5137 Gus Young Ln, Edina, MN 55436-1530 Ph: (952) 641-6226 |
News Archive
Rettsyndrome.org is pleased to share that Neuren Pharmaceuticals, today, after meeting with the FDA, will conduct a Phase 3 clinical trial for trofinetide, a compound that shows great promise in the treatment of Rett syndrome, in children and adults.
Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of its developmental retinitis pigmentosa (RP) treatment, jCell.
At the 64th ASMS Conference, Bruker introducesrapifleX™, the highest performance MALDI-TOF/TOF mass spectrometer, which had been shown as work-in-progress to early adopters at HUPO 2015.
People living with a child who attends school in-person have an increased risk of reporting evidence of COVID-19, but teacher masking, symptom screening, and other mitigation measures in schools may be able to minimize that excess risk, suggests a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Telephone-based counseling, when combined with physician advice, can help breast cancer survivors become more physically active, which can improve quality of life and lessen the side effects of cancer treatment, according to new research from The Miriam Hospital.
› Verified 2 days ago
Dr. Tamra L Larson, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3300 Edinborough Way Ste 412, Edina, MN 55435 Phone: 952-835-3201 | |
Thomas L Elton, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 7000 York Ave S, Edina, MN 55435 Phone: 952-929-1159 Fax: 952-922-9308 | |
Dr. Paul J Shlafer, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3333 Hazelton Rd, Edina, MN 55435 Phone: 952-926-5300 Fax: 952-926-2729 | |
Dr. Joel Woods, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2915 Southdale Ctr, Edina, MN 55435 Phone: 952-920-8607 | |
Dr. Kim Thi Nguyen, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2195 Southdale Ctr, Edina, MN 55435 Phone: 952-920-8607 | |
Toni Albrecht, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3380 Galleria, Edina, MN 55435 Phone: 952-920-5458 | |
Deanna E Harter, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3939 W 50th St Ste 200, Edina, MN 55424 Phone: 952-920-2020 Fax: 952-920-3225 |